Loading ...

Swallowing a capsule that releases microscopic robots capable of delivering drugs directly to the intestinal lining or performing biopsies without invasive procedures may soon move closer to clinical reality. Research on targeted drug delivery (TDD) and medical microrobotics is advancing rapidly, particularly in gastrointestinal (GI) medicine, where improving drug absorption and therapeutic efficacy remain a major challenge.

Oral administration has long been considered the most convenient route for drug delivery. It requires minimal technical expertise, is minimally invasive, and, unlike injections, avoids discomfort, wound infections, and procedural complications — factors that contribute to improved treatment adherence.

However, growing scientific evidence has shown that the effectiveness of oral drug administration is often limited by biological barriers within the GI tract that restrict the bioavailability and absorption of drugs.

Oral Delivery and Targeted Systems

Against this backdrop, GI-TTD has become a major area of investigation, with researchers exploring strategies to overcome these barriers while advancing closer to the principles of precision medicine.

One major area of research involves the use of nanomotors, particularly in the treatment of digestive diseases. According to recent reports published in Springer Nature, these systems are distinguished by their ability to localize targets precisely within the body through autonomous driving forces generated either by external forces or internal environmental effects. This approach allows prolonged retention within specific anatomic sites, including the stomach and small intestinal mucosa, potentially substantially improving drug utilization.

These technologies have driven the development of multiple TDD platforms, including microspheres, microrobots, and nanoparticles. Potential applications include gene therapy, oncology, diagnostics, and microsurgery.

Microrobots Design and Future Medicine

When focusing on microrobots, what stands out is not only their mechanism of action, but also the innovation in the materials used. Biohybrid microrobots, for example, combine living biological components with synthetic materials. These systems integrate natural biological systems, such as bacteria, algae, or mammalian cells, with synthetic structures, such as nanoparticles and polymers. This is aimed at achieving more efficient and precise therapeutic delivery.

Mechanisms such as pH sensitivity, temperature responsiveness, and enzyme-activated drug release enhance their ability to deliver drugs precisely to the target site. Thus, they offer solutions for localized therapies and reduce side effects. However, despite advances in this field, challenges regarding biocompatibility, stability, scalability, and regulatory issues remain.

Another emerging technology involves 3D-printed rotating magnetic microrobots designed specifically for in vivo TDD. Cell proliferation and viability studies have supported their biocompatibility, and researchers believe that these devices may offer efficient drug delivery to the colon and large intestine.

Among the most recent developments are fully metallic biodegradable microrobots, which could revolutionize both drug delivery and biopsy procedures. Presented at Digestive Disease Week (DDW) 2026, Chicago, these small, shape-shifting metal robots could administer medications and collect biopsy samples painlessly for one day and then safely dissolve without needing to be removed.

The findings were presented by Ling Li, MD, PhD, instructor of medicine in the Division of Gastroenterology and Hepatology at the Johns Hopkins University School of Medicine, Baltimore.

“Existing biodegradable microrobots are made from materials such as polymers or hydrogels that biodegrade but lack the strength and rigidity that allow our fully metallic microrobots to penetrate and cut tissue, leaving no trace once their work is complete,” said Li.

These findings suggest that the use of microrobots could eventually replace some conventional, uncomfortable, and invasive endoscopic procedures with simply swallowing a capsule. The capsule would travel inside the body, where, similar to tiny transformers, the preprogrammed microrobots would change shape upon reaching their destination to form minuscule tweezers capable of collecting tissue samples from areas that are difficult to access using traditional methods.

Researchers have also reported that these devices could transform into microinjectors for administering medications, offering an alternative to intravenous injections or infusions for the administration of biologic therapies.

One of the most clinically important aspects of this research involves these microrobots, which also show potential for the delivery of biologics, such as anti-TNF agents and GLP-1 receptor agonists. Researchers believe that these microrobots may improve drug absorption by releasing medications directly beneath the GI mucosa while reducing the need for repeated injections or clinic visits.

Researchers presenting at DDW 2026 also reported that the biodegradation timing can be controlled by adjusting the thickness of the metallic layers. “We can control the degradation rate from minutes to months, depending on the application,” the researchers noted.

“We believe that these all-metal, biodegradable devices represent a major breakthrough in the effort to unlock the full potential of medical microrobots. We don’t have to choose between durability and safety. We can have both,” Li concluded.

Although these technologies remain in preclinical development, advances in medical microrobotics are moving the field closer to treatments that are more precise, less invasive, and targeted directly toward specific tissues. Researchers believe that these developments may eventually improve treatment efficacy, therapeutic adherence, and patient quality of life.

This article was translated from El Médico Interactivo on Univadis, part of the Medscape Professional Network.